Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-03-22 00:00:00 ET · period of report 2024-03-20 · accession 0001415889-24-009019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-22 | 2024-03-20 | ELVN | Ballal Rahul D. | Dir | M - OptEx | $5.52 | +13.3K | 35.6K | +59% | +$73.3K |
| D | 2024-03-22 | 2024-03-20 | ELVN | Ballal Rahul D. | Dir | S - Sale+OE | $19.16 | -13.3K | 22.3K | -37% | -$254.4K |
| D | 2024-03-22 | 2024-03-20 | ELVN | Ballal Rahul D. | Dir | M - OptEx | $0.00 | -13.3K | 19.6K | -40% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-20 | M | A | 13,278 | $5.52 | 35,619 | D | — | — | (F2) The number of shares beneficially owned (i) reflects the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split") and (ii) has been adjusted following an internal review of the Reporting Person's holdings. |
| 2 | Common | Common Stock | 2024-03-20 | S | D | 13,278 | $19.16 | 22,341 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $19.005 to $19.405. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Derivative | Stock Option (right to buy) | 2024-03-20 | M | D | 13,278 | $0.00 | 19,571 | D | $5.52 · — to 2032-01-27 | 13,278 Common Stock | (F2) The number of shares beneficially owned (i) reflects the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split") and (ii) has been adjusted following an internal review of the Reporting Person's holdings. (F4) The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter. |